PF 4523655

Drug Profile

PF 4523655

Alternative Names: PF-04523655; PF-4523655; PF-655; PFE-4523655; REDD-14-NP; RTP 801i-14; RTP-801i

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Quark Pharmaceuticals
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 17 Jun 2015 Phase-II development is ongoing for diabetic macular oedema and wet age-related macular degeneration USA, European Union, Asia, Latin America and the Middle East
  • 02 May 2012 Quark and Pfizer amend their licensing agreement for PF 4523655 to allow Quark to conduct a phase IIa trial of the product in patients with open-angle glaucoma
  • 11 Aug 2011 PF 4523655 is no longer licensed to Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top